CN1680333A - 用于治疗病毒性疾病的吡唑衍生物 - Google Patents

用于治疗病毒性疾病的吡唑衍生物 Download PDF

Info

Publication number
CN1680333A
CN1680333A CNA2005100088329A CN200510008832A CN1680333A CN 1680333 A CN1680333 A CN 1680333A CN A2005100088329 A CNA2005100088329 A CN A2005100088329A CN 200510008832 A CN200510008832 A CN 200510008832A CN 1680333 A CN1680333 A CN 1680333A
Authority
CN
China
Prior art keywords
alkyl
substituted
methyl
phenyl
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005100088329A
Other languages
English (en)
Chinese (zh)
Inventor
B·W·迪莫克
P·S·约内斯
J·H·梅里特
M·J·帕拉特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1680333A publication Critical patent/CN1680333A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2005100088329A 2000-10-10 2001-10-04 用于治疗病毒性疾病的吡唑衍生物 Pending CN1680333A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0024795.7 2000-10-10
GBGB0024795.7A GB0024795D0 (en) 2000-10-10 2000-10-10 Pyrazole derivatives for the treatment of viral diseases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB018171710A Division CN1191239C (zh) 2000-10-10 2001-10-04 用于治疗病毒性疾病的吡唑衍生物

Publications (1)

Publication Number Publication Date
CN1680333A true CN1680333A (zh) 2005-10-12

Family

ID=9900999

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2005100088329A Pending CN1680333A (zh) 2000-10-10 2001-10-04 用于治疗病毒性疾病的吡唑衍生物
CNB018171710A Expired - Fee Related CN1191239C (zh) 2000-10-10 2001-10-04 用于治疗病毒性疾病的吡唑衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB018171710A Expired - Fee Related CN1191239C (zh) 2000-10-10 2001-10-04 用于治疗病毒性疾病的吡唑衍生物

Country Status (28)

Country Link
US (2) US6699887B2 (enExample)
EP (1) EP1326843A1 (enExample)
JP (1) JP4015548B2 (enExample)
KR (1) KR100534158B1 (enExample)
CN (2) CN1680333A (enExample)
AR (1) AR030858A1 (enExample)
AU (2) AU2002221651B2 (enExample)
BR (1) BR0114483A (enExample)
CA (1) CA2423515A1 (enExample)
CZ (1) CZ20031297A3 (enExample)
EC (1) ECSP034547A (enExample)
GB (1) GB0024795D0 (enExample)
GT (1) GT200100201A (enExample)
HR (1) HRP20030251A2 (enExample)
HU (1) HUP0302722A2 (enExample)
IL (1) IL154875A0 (enExample)
MA (1) MA26951A1 (enExample)
MX (1) MXPA03003070A (enExample)
NO (1) NO20031615L (enExample)
NZ (1) NZ524740A (enExample)
PA (1) PA8530301A1 (enExample)
PE (1) PE20020750A1 (enExample)
PL (1) PL362918A1 (enExample)
RU (1) RU2270832C2 (enExample)
UY (1) UY26956A1 (enExample)
WO (1) WO2002030907A1 (enExample)
YU (1) YU27203A (enExample)
ZA (1) ZA200302519B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083005A1 (en) * 2000-09-29 2009-07-29 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
GB0113524D0 (en) 2001-06-04 2001-07-25 Hoffmann La Roche Pyrazole derivatives
US7230025B2 (en) 2002-09-26 2007-06-12 Pfizer, Inc. Pyrazole derivatives
EP1546132A1 (en) * 2002-09-26 2005-06-29 Pfizer Limited Pyrazole derivatives as reverse transcriptase inhibitors
DE60319254T2 (de) 2002-09-26 2009-02-12 Pfizer Inc. Pyrazolamide zur behandlung von hiv-infektionen
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
GB0223234D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
GB0223232D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
CA2518823A1 (en) * 2003-03-24 2004-10-07 F.Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
CA2569530C (en) * 2004-07-01 2013-07-30 Daiichi Asubio Pharma Co.,Ltd. Thienopyrazole derivative having pde 7 inhibitory activity
US20070005049A1 (en) * 2005-06-30 2007-01-04 Comben Richard H Apparatus and Method of Treating Urinary Incontinence by Heating Urethra
AU2007270814B2 (en) * 2006-07-05 2011-07-14 Pfizer Products Inc. Pyrazole derivatives as cytochrome P450 inhibitors
PL2057125T3 (pl) * 2006-08-16 2011-09-30 Hoffmann La Roche Nienukleozydowe inhibitory odwrotnej transkryptazy
GB0713479D0 (en) * 2007-07-11 2007-08-22 Syngenta Participations Ag Substituted aromatic heterocyclic compounds as fungicides
RU2495878C2 (ru) 2007-12-21 2013-10-20 Ф.Хоффманн-Ля Рош Аг Гетероциклические антивирусные соединения
GB0823000D0 (en) * 2008-12-17 2009-01-28 Syngenta Participations Ag Isothiazole and pyrazole derivatives with plant growth regulating properties
NZ595233A (en) 2009-02-25 2013-01-25 Daiichi Sankyo Co Ltd Tricyclic pyrazolopyrimidine derivatives
FR2951549B1 (fr) 2009-10-15 2013-08-23 Olivier Schussler Procede d'obtention de bioprotheses medicales implantables
EP2610260A4 (en) 2010-08-23 2014-01-15 Daiichi Sankyo Co Ltd CRYSTAL OF TRICYCLIC PYRAZOLPYRIMIDINE DERIVATIVE
WO2012026433A1 (ja) 2010-08-23 2012-03-01 第一三共株式会社 三環性ピラゾロピリミジン誘導体のフリー体結晶
WO2014074628A1 (en) * 2012-11-08 2014-05-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compounds for treating hiv and methods for using the compounds
US9925190B2 (en) 2015-02-16 2018-03-27 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting HIV-1 Nef
EP3778583B1 (en) 2018-03-30 2025-06-18 Sumitomo Chemical Company, Limited Heterocyclic compound and arthropod pest control composition containing same
WO2020081856A1 (en) * 2018-10-18 2020-04-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibitors of hiv-1 nef for the treatment of hiv disease
FR3121927B1 (fr) 2021-04-19 2023-03-31 Eiffage Genie Civil Terrassement Procédé d’inertage des boues d’excavation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627423A4 (en) 1992-01-22 1995-02-15 Nissan Chemical Ind Ltd SUBSTITUTED PYRAZOLE DERIVATIVES AND BACTERICIDES FOR AGRICULTURE AND GARDENING.
BR9307664A (pt) * 1992-12-17 1999-06-29 Pfizer Pirazóis substituídos como antagonistas
US6005109A (en) 1997-10-30 1999-12-21 Pflizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
WO1994013643A1 (en) * 1992-12-17 1994-06-23 Pfizer Inc. Pyrazoles and pyrazolopyrimidines having crf antagonist activity
TW336932B (en) * 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
WO2006027423A1 (fr) * 2004-08-09 2006-03-16 Simag Developpement Dispositif de saisie comportant un capteur optique suivi d’un moyen de filtrage

Also Published As

Publication number Publication date
CA2423515A1 (en) 2002-04-18
YU27203A (sh) 2006-05-25
CN1469865A (zh) 2004-01-21
ECSP034547A (es) 2003-05-26
CN1191239C (zh) 2005-03-02
GT200100201A (es) 2002-05-23
PL362918A1 (en) 2004-11-02
IL154875A0 (en) 2003-10-31
WO2002030907A1 (en) 2002-04-18
AU2165102A (en) 2002-04-22
MA26951A1 (fr) 2004-12-20
ZA200302519B (en) 2004-06-30
AU2002221651B2 (en) 2006-10-19
KR100534158B1 (ko) 2005-12-06
UY26956A1 (es) 2002-04-26
HK1061021A1 (en) 2004-09-03
JP2004511469A (ja) 2004-04-15
AR030858A1 (es) 2003-09-03
US6699887B2 (en) 2004-03-02
NO20031615D0 (no) 2003-04-09
CZ20031297A3 (cs) 2004-01-14
GB0024795D0 (en) 2000-11-22
HRP20030251A2 (en) 2005-02-28
BR0114483A (pt) 2003-07-01
US20040192752A1 (en) 2004-09-30
US20030018197A1 (en) 2003-01-23
RU2270832C2 (ru) 2006-02-27
JP4015548B2 (ja) 2007-11-28
MXPA03003070A (es) 2003-07-14
NO20031615L (no) 2003-05-23
PA8530301A1 (es) 2002-07-30
PE20020750A1 (es) 2002-08-21
HUP0302722A2 (hu) 2003-12-29
RU2003112610A (ru) 2005-02-20
EP1326843A1 (en) 2003-07-16
KR20030046492A (ko) 2003-06-12
US7183296B2 (en) 2007-02-27
NZ524740A (en) 2005-09-30

Similar Documents

Publication Publication Date Title
CN1680333A (zh) 用于治疗病毒性疾病的吡唑衍生物
CN1165536C (zh) 与六元杂环稠合的取代的吡唑衍生物
CN1150192C (zh) 作为趋化细胞因子受体5调制剂的哌啶
CN1274676C (zh) 喹啉和喹唑啉衍生物
CN100339376C (zh) 含氮芳环衍生物
CN1788001A (zh) 可用于治疗赘生性疾病、炎性和免疫系统病症的2,4－二(苯氨基)嘧啶
CN1832928A (zh) 以5元杂环为基础的p38激酶抑制剂
CN1582285A (zh) 用作糖原合酶激酶3β抑制剂(GSK3抑制剂)的杂芳胺化合物
CN1214339A (zh) 吡唑衍生物、其制备方法和在药物中的应用
CN1555367A (zh) 3-取代的-4-嘧啶酮衍生物
CN1198804C (zh) 酰胺化合物及其用途
CN1516691A (zh) 苯基吡啶甲酰哌嗪衍生物
CN1688573A (zh) 糖原合成酶激酶3的吡咯基抑制剂
CN1942465A (zh) Akt活性抑制剂
CN1764650A (zh) 2,3,6－三取代的－4－嘧啶酮衍生物
CN1703405A (zh) 用作糖原合酶激酶3β抑制剂的氨基苯甲酰胺衍生物
CN1628109A (zh) 新颖的芳基－与杂芳基－哌嗪
CN1791410A (zh) 通过抑制jnk治疗或预防炎性或代谢性病症的方法
CN1921885A (zh) Sr蛋白质的磷酸化控制方法以及以sr蛋白质活性控制剂为有效成分的抗病毒剂
CN1627945A (zh) 作为npy拮抗剂的喹啉衍生物
CN1049219C (zh) 具有内皮素拮抗活性的芳香杂环并环戊烯衍生物
CN1751028A (zh) 非核苷逆转录酶抑制剂
CN1933830A (zh) 吲哚衍生物和其作为激酶抑制剂特别是ikk2抑制剂的用途
CN1297442A (zh) 用作抗癌剂和抗增殖剂的5－氨基茚并[1,2－c]吡唑－4－酮类化合物
CN1656086A (zh) 苯并呋喃衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication